Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Zandelisib Elicits High Response in Relapsed/Refractory Follicular Lymphoma

June 12th 2022

Zandelisib, a potent and selective oral PI3Kδ inhibitor, elicited a high overall response rate as a single agent in heavily pretreated patients with relapsed or refractory follicular lymphoma, according to data from the phase 2 TIDAL trial.

Obinutuzumab/Chemo Maintains Superior PFS in Untreated Follicular Lymphoma at 8 Years

June 12th 2022

The combination of obinutuzumab plus chemotherapy delivered superior long-term progression-free survival benefit for patients with treatment-naïve follicular lymphoma.

R-CODOX-M/R-IVAC Fails to Establish Superior Efficacy Over DA-EPOCH-R in High-Risk Burkitt Lymphoma

June 12th 2022

Treatment with the R-CODOX-M and R-IVAC regimens elicited similar efficacy to dose-adjusted infused DA-EPOCH-R in patients with newly diagnosed, high-risk Burkitt lymphoma.

Epcoritamab Elicits Impressive Responses in Relapsed/Refractory LBCL

June 11th 2022

The first-in-class, subcutaneously administered T-cell–engaging bispecific antibody epcoritamab demonstrated deep and durable responses in patients with relapsed/refractory large B-cell lymphoma.

Mosunetuzumab Approved in Europe for Relapsed/Refractory Follicular Lymphoma

June 8th 2022

The European Commission has granted a conditional marketing authorization for mosunetuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 systemic therapies.

Zanubrutinib Plus Obinutuzumab Elicits Improved Response Rates in Relapsed/Refractory Follicular Lymphoma

June 7th 2022

The addition of zanubrutinib to obinutuzumab achieved an improved overall response rate, overall survival, and progression-free survival, compared with obinutuzumab alone, in patients with relapsed/refractory follicular lymphoma.

OncLive Honors 13 Cancer Care Pioneers

June 2nd 2022

For the 10th consecutive year, OncLive® is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

FDA Withdraws Approvals for Umbralisib in MZL, Follicular Lymphoma Due to Safety Concerns

June 1st 2022

The FDA announced that it has withdrawn approval for umbralisib, an oral inhibitor of PI3K-δ and CK1-ε manufactured by TG Therapeutics.

Nurix Therapeutics Launches Expansion Cohort Evaluating NX-2127 in CLL

May 31st 2022

Nurix Therapeutics has initiated an ongoing phase 1 trial to examine NX-2127, an immunomodulatory oral BTK inhibitor, in patients with chronic lymphocytic leukemia.

FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma

May 27th 2022

The FDA has granted accelerated approval to tisagenlecleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.

Zanubrutinib Approved in Uruguay for MCL, MZL, and Waldenström Macroglobulinemia

May 27th 2022

The BTK inhibitor zanubrutinib has been approved in Uruguay for the treatment of adult patients with previously treated mantle cell lymphoma, relapsed or refractory marginal zone lymphoma, and Waldenström macroglobulinemia.

Polatuzumab Vedotin Plus R-CHP Approved in Europe for Previously Untreated DLBCL

May 26th 2022

The European Commission has approved the combination of polatuzumab vedotin and rituximab and cyclophosphamide, doxorubicin, and prednisone for use in adult patients with previously untreated diffuse large B-cell lymphoma.

Tisagenlecleucel Approved in Europe for Relapsed/Refractory Follicular Lymphoma

May 17th 2022

The European Commission has approved the CD19-targeting chimeric antigen receptor T-cell agent tisagenlecleucel for the treatment of adults with relapsed/refractory follicular lymphoma following at least 2 lines of systemic therapy.

Finding the Underlying Mutations Driving CAR-T Failure

May 17th 2022

New research illuminates the mechanisms that make B-cell lymphomas resistant to important immunotherapy

New Treatment Options Are in Play for Relapsed/ Refractory DLBCL

May 12th 2022

Up to 40% of patients with diffuse large B-cell lymphoma are refractory to or relapse after first-line treatment.

Dr. Westin on the Evolving Landscape of CAR T-Cell Therapy in NHL

May 3rd 2022

Jason R. Westin, MD, discusses the evolving landscape of CAR T-cell therapy in non-Hodgkin lymphoma.

Second-Line Axi-Cel Offers a “Practice-Changing” Indication for LBCL

May 3rd 2022

Lori A. Leslie, MD, reviews how the approval of axicabtagene ciloleucel may impact or enhance current practice patterns for adult patients with large B-cell lymphoma.

Very Low Dose Radiation Therapy Demonstrates Efficacy in Indolent Non-Hodgkin Lymphoma

May 2nd 2022

Although it is not considered to be a standard of care for patients with indolent non-Hodgkin lymphoma, very low dose radiation therapy was found to have efficacy in the palliative setting and to allow for retreatment to the same field when needed.

Mosunetuzumab Approaches EU Approval for Relapsed or Refractory Follicular Lymphoma

April 25th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval under conditional marketing authorization for mosunetuzumab for use in adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 therapies.

Match-Adjusted Comparison Shows Comparable Efficacy Outcomes for Axi-cel and Tisa-cel in Follicular Lymphoma

April 25th 2022

Results of a match-adjusted analysis of patients with follicular lymphoma treated with axicabtagene ciloleucel in ZUMA-5 trial vs those treated with tisagenlecleucel in ELARA showed a similar efficacy profile between the 2 cellular therapies.